A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis. | MicrobiomeTrials
A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis.
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-11-01Est. Completion: 2026-06
Enrollment target: 100 participants
Locations
Dr. Rudy Gutierrez Diaz Sede Central, Guatemala City, Guatemala
EyeScan, Imágenes Diagnósticas Oculares, S. A., Guatemala City, Guatemala
Other microbiome trials you might be interested in